The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis
Megan Crumbaker, Eva KF Chan, Tingting Gong, Niall Corcoran, Weerachai Jaratlerdsiri, Ruth J Lyons, Anne-Maree Haynes, Anna A Kulidjian, Anton MF Kalsbeek, Desiree C Petersen, Phillip D Stricker, Christina AM Jamieson, Peter I Croucher, Christopher M Hovens, Anthony M Joshua, Vanessa M Hayes
Cancers | MDPI | Published : 2020
BACKGROUND: While critical insights have been gained from evaluating the genomic landscape of metastatic prostate cancer, utilizing this information to inform personalized treatment is in its infancy. We performed a retrospective pilot study to assess the current impact of precision medicine for locally advanced and metastatic prostate adenocarcinoma and evaluate how genomic data could be harnessed to individualize treatment. METHODS: Deep whole genome-sequencing was performed on 16 tumour-blood pairs from 13 prostate cancer patients; whole genome optical mapping was performed in a subset of 9 patients to further identify large structural variants. Tumour samples were derived from prostate, ..View full abstract
This work was funded by the Movember Australia and the Prostate Cancer Foundation Australia (PCFA) as part of the Movember Revolutionary Team Award (MRTA) to the Garvan Institute of Medical Research on prostate cancer bone metastasis (ProMis led by P.I.C. with team leads V.M.H., N.C. and C.M.H.), and an Ian Potter Foundation infrastructure award to V.M.H.. M.C. and T.G. was funded by an Australian Government Research Training Program Scholarship, E.K.F.C. and D.C. by MRTA-ProMis, W.J. by the Australian Prostate Cancer Research Centre NSW (APCRC-NSW), and V.M.H. by the University of Sydney Foundation and Petre Foundation, Australia.